Auxly/FSD streaming dealClearly people talk sht on this board and post misleading information without doing proper DD. "As disclosed on Wednesday, Feb. 6, FSD terminated the definitive agreement with Auxly. FSD believes that Auxly was under clear obligation to develop all aspects of the company's cannabis cultivation facility in mutually agreed upon staged phases. Auxly issued a press release on July 3, 2018, in which they anticipated that the first phase of construction would be completed and ready for Health Canada approval by the end of December, 2018. We simply couldn't wait any longer for our vendor to perform its obligations and therefore we terminated the agreement," said Dr. Raza Bokhari, executive co-chairman and interim chief executive officer. Dr. Bokhari continued: "Under the terms and conditions of the streaming agreement, FSD Pharma and Auxly are subject to a number of non-disclosure obligations that survive the termination. FSD Pharma intends to continue to live up to its surviving obligations, we are hopeful that Auxly will do the same." About FSD Pharma Inc. FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The company has 25,000 square feet available for production at its Ontario facility with an additional 220,000 square feet currently in development (with an estimated cost of $250 per square foot to be completed in 2019). We seek Safe Harbor. 2019 Canjex Publishing Ltd. All rights reserved.